AngioDynamics, Inc.  

(Public, NASDAQ:ANGO)   Watch this stock  
Find more results for ANGO
10.67
-0.02 (-0.19%)
May 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.59 - 10.76
52 week 9.52 - 12.91
Open 10.63
Vol / Avg. 95,486.00/118,828.00
Mkt cap 373.98M
P/E     -
Div/yield     -
EPS -0.26
Shares 35.05M
Beta 0.66
Inst. own 95%
Jul 8, 2013
Q4 2013 AngioDynamics Earnings Release Add to calendar
May 21, 2013
AngioDynamics at UBS Global Healthcare Conference
Apr 9, 2013
Q3 2013 AngioDynamics Earnings Conference Call
Apr 3, 2013
Q3 2013 AngioDynamics Earnings Release
Mar 12, 2013
AngioDynamics at Barclays Healthcare Conference
Mar 8, 2013
Q3 2013 Preliminary AngioDynamics Earnings Conference Call
Feb 26, 2013
AngioDynamics at RBC Capital Markets' Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Feb '13) 2012
Net profit margin -1.22% -2.30%
Operating margin 0.07% -1.34%
EBITD margin - 11.84%
Return on average assets -0.51% -0.88%
Return on average equity -0.75% -1.10%
Employees 1,400 -
Carbon Disclosure Rating - -

Address

14 Plaza Drive
LATHAM, NY 12110
United States - Map
+1-518-7951400 (Phone)
+1-518-7951401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

AngioDynamics, Inc. designs manufacture and sell a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company�s segments include vascular segment and Oncology/Surgery. The Vascular segment, which is responsible for products targeting the venous intervention, dialysis access, thrombus management and peripheral disease markets. The Oncology/Surgery segment, which is responsible for radio frequency (RF) and microwave ablation, embolization, NanoKnife and Habib product lines. On May 21, 2012, the Company acquired Navilyst Medical. In October 2012, the Company acquired Vortex Medical Inc. In February 2013, it acquired certain assets of Microsulis Medical Ltd.

Officers and directors

Vincent A. Bucci Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Joseph M. DeVivo President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Mark T. Frost Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
George W. Bourne Senior Vice President, Chief Technology & Operations Officer
Age: 52
Bio & Compensation  - Reuters
Stephen J. McGill Senior Vice President, General Manager - International
Age: 51
Bio & Compensation  - Reuters
Alan Panzer Senior Vice President, General Manager - US Sales
Age: 51
Bio & Compensation  - Reuters
Matthew Kapusta Senior Vice President - Business Development
Age: 40
Bio & Compensation  - Reuters
Louis J. Mazzarese Senior Vice President, Chief Regulatory Officer
Bio & Compensation  - Reuters
John J. Soto Senior Vice President - Global Franchise, Peripheral Vascular
Bio & Compensation  - Reuters
Richard A. Stark Senior Vice President - Global Franchise, Oncology/Surgery
Age: 47
Bio & Compensation  - Reuters